2008 - Fellow of the Royal Society of Edinburgh
Fellow of The Academy of Medical Sciences, United Kingdom
Iain B. McInnes spends much of his time researching Immunology, Arthritis, Rheumatoid arthritis, Internal medicine and Inflammation. The various areas that Iain B. McInnes examines in his Arthritis study include Proinflammatory cytokine, Interleukin 18 and Intensive care medicine. In his work, Pathogenesis and Systemic inflammation is strongly intertwined with Disease, which is a subfield of Rheumatoid arthritis.
His work carried out in the field of Internal medicine brings together such families of science as Placebo and Surgery. His Cytokine research is multidisciplinary, relying on both Interleukin 12 and Cell biology. His Psoriatic arthritis research incorporates themes from Physical therapy, Ankylosing spondylitis and Ustekinumab.
His primary areas of investigation include Immunology, Internal medicine, Rheumatoid arthritis, Arthritis and Psoriatic arthritis. Iain B. McInnes interconnects Gastroenterology, Placebo, Surgery and Endocrinology in the investigation of issues within Internal medicine. Iain B. McInnes focuses mostly in the field of Rheumatoid arthritis, narrowing it down to matters related to Disease and, in some cases, Bioinformatics.
His research in Inflammatory arthritis and Synovial membrane are components of Arthritis. His study in the field of Secukinumab is also linked to topics like In patient. His study in Inflammation is interdisciplinary in nature, drawing from both Pathogenesis and Pathology.
Internal medicine, Psoriatic arthritis, Rheumatoid arthritis, Secukinumab and Arthritis are his primary areas of study. The various areas that Iain B. McInnes examines in his Internal medicine study include Gastroenterology, Placebo and Oncology. His work on Guselkumab is typically connected to In patient as part of general Psoriatic arthritis study, connecting several disciplines of science.
His Rheumatoid arthritis study is concerned with the larger field of Immunology. His Secukinumab study incorporates themes from Adalimumab and Infliximab. The study incorporates disciplines such as Rheumatism, Clinical trial and Randomized controlled trial in addition to Arthritis.
Iain B. McInnes mainly focuses on Internal medicine, Rheumatoid arthritis, Psoriatic arthritis, Arthritis and Rheumatology. His Internal medicine research is multidisciplinary, incorporating elements of Placebo and Genome-wide association study. His Rheumatoid arthritis research incorporates elements of Methotrexate, Oncology, Intensive care medicine, Rheumatism and Disease.
He has researched Psoriatic arthritis in several fields, including Inflammatory bowel disease, Ankylosing spondylitis and Inflammatory arthritis. His studies in Arthritis integrate themes in fields like Cell, Cancer research, Clinical trial, Transcriptome and Abatacept. In his research on the topic of Cytokine, Immunology is strongly related with Autocrine signalling.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The pathogenesis of rheumatoid arthritis.
Iain B. McInnes;Georg Schett.
The New England Journal of Medicine (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados.
Revmatologiia (2011)
Cytokines in the pathogenesis of rheumatoid arthritis
Iain B. McInnes;Georg Schett.
Nature Reviews Immunology (2007)
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld.
Annals of the Rheumatic Diseases (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
M J Peters;D P M Symmons;D McCarey;B A Dijkmans.
Annals of the Rheumatic Diseases (2010)
Explaining How “High-Grade” Systemic Inflammation Accelerates Vascular Risk in Rheumatoid Arthritis
Naveed Sattar;David W. McCarey;Hilary Capell;Iain B. McInnes.
Circulation (2003)
Evidence that cytokines play a role in rheumatoid arthritis
Fionula M. Brennan;Iain B. McInnes.
Journal of Clinical Investigation (2008)
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
David W McCarey;Iain B McInnes;Rajan Madhok;Rosie Hampson.
The Lancet (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Glasgow
University of Glasgow
University of Washington
University of Glasgow
Tan Tock Seng Hospital
University of Glasgow
Leiden University Medical Center
University of Leeds
University of California, San Diego
University of Oxford
University of Oulu
Harvard University
Intuitive Surgical (Switzerland)
University of Auckland
University of Newcastle Australia
Pennsylvania State University
Duke University
University of Sydney
University of Florida
Yale University
University of British Columbia
University of Dundee
University of Oxford
Yale University
Emory University
University of Chicago